ApoB and apoM – New aspects of lipoprotein biology in uremia‐induced atherosclerosis

[1]  S. Schwartz.  Faculty Opinions recommendation of Corrigendum: KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  A. Webster,et al.  Chronic Kidney Disease , 2017, The Lancet.

[3]  C. Wanner,et al.  HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.

[4]  L. Nielsen,et al.  Uremia modulates the phenotype of aortic smooth muscle cells. , 2017, Atherosclerosis.

[5]  R. San Martín,et al.  The cellular and signalling alterations conducted by TGF-β contributing to renal fibrosis. , 2016, Cytokine.

[6]  S. Crooke,et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[7]  Vagheesh M. Narasimhan,et al.  Extensive Proliferation of a Subset of Differentiated, yet Plastic, Medial Vascular Smooth Muscle Cells Contributes to Neointimal Formation in Mouse Injury and Atherosclerosis Models , 2016, Circulation research.

[8]  A. Ushiyama,et al.  Glycocalyx and its involvement in clinical pathophysiologies , 2016, Journal of Intensive Care.

[9]  J. Tarbell,et al.  Endothelial glycocalyx, apoptosis and inflammation in an atherosclerotic mouse model. , 2016, Atherosclerosis.

[10]  M. Landray,et al.  Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. , 2016, The lancet. Diabetes & endocrinology.

[11]  F. Hobbs,et al.  Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis , 2016, PloS one.

[12]  J. Tarbell,et al.  The glycocalyx and its significance in human medicine , 2016, Journal of internal medicine.

[13]  N. Vaziri.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. , 2016, Kidney international.

[14]  J. Tarbell,et al.  Sphingosine‐1‐phosphate Maintains Normal Vascular Permeability by Preserving Endothelial Surface Glycocalyx in Intact Microvessels , 2016, Microcirculation.

[15]  J. Yun,et al.  Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[16]  S. Swendeman,et al.  Impaired endothelial barrier function in apolipoprotein M‐deficient mice is dependent on sphingosine‐1‐phosphate receptor 1 , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  H. Daida,et al.  Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. , 2016, International journal of cardiology.

[18]  J. Mattana,et al.  Cholesterol Metabolism in CKD. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  J. Tarbell,et al.  Sphingosine 1-phosphate induced synthesis of glycocalyx on endothelial cells. , 2015, Experimental cell research.

[20]  P. Olinga,et al.  Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes , 2015, Front. Med..

[21]  M. Reilly,et al.  Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study , 2015, BMC Nephrology.

[22]  S. Hazen,et al.  Protein Carbamylation and Cardiovascular Disease , 2015, Kidney international.

[23]  Laura S. Shankman,et al.  KLF4 Dependent Phenotypic Modulation of SMCs Plays a Key Role in Atherosclerotic Plaque Pathogenesis , 2015, Nature Medicine.

[24]  H. Pavenstädt,et al.  Damage of the endothelial glycocalyx in chronic kidney disease. , 2014, Atherosclerosis.

[25]  B. Lévy,et al.  Smooth Muscle Cell Phenotypic Switching in Stroke , 2014, Translational Stroke Research.

[26]  N. Vaziri,et al.  Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  N. Vaziri.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease , 2014, Clinical and Experimental Nephrology.

[28]  J. Madenspacher,et al.  Apolipoprotein E-Deficient Mice Are Susceptible to the Development of Acute Lung Injury , 2014, Respiration.

[29]  J. Tarbell,et al.  Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. , 2014, American journal of physiology. Heart and circulatory physiology.

[30]  A. Gafencu,et al.  The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. , 2013, Immunobiology.

[31]  Chi Pang Wen,et al.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention , 2013, The Lancet.

[32]  V. Jha,et al.  Chronic kidney disease: global dimension and perspectives , 2013, The Lancet.

[33]  Kai-Uwe Eckardt,et al.  Evolving importance of kidney disease: from subspecialty to global health burden , 2013, The Lancet.

[34]  C. Christoffersen,et al.  Osteopontin deficiency dampens the pro-atherogenic effect of uraemia. , 2013, Cardiovascular research.

[35]  S. Hazen,et al.  Protein carbamylation predicts mortality in ESRD. , 2013, Journal of the American Society of Nephrology : JASN.

[36]  R. Horton,et al.  Visualization of splenic marginal zone B cell shuttling and follicular B cell egress , 2012, Nature.

[37]  L. Belo,et al.  Oxidized low‐density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene , 2012, Hemodialysis international. International Symposium on Home Hemodialysis.

[38]  S. Rafii,et al.  Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. , 2012, Developmental cell.

[39]  S. Harper,et al.  Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. , 2012, Journal of the American Society of Nephrology : JASN.

[40]  G. Owens,et al.  Smooth muscle cell phenotypic switching in atherosclerosis. , 2012, Cardiovascular research.

[41]  C. Stancu,et al.  Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis , 2012, Cell and Tissue Research.

[42]  W. Hörl,et al.  Serum amyloid A in uremic HDL promotes inflammation. , 2012, Journal of the American Society of Nephrology : JASN.

[43]  T. Lüscher,et al.  Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.

[44]  J. Jankowski,et al.  High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. , 2012, Cardiovascular research.

[45]  E. Samouilidou,et al.  Lipid Abnormalities and Oxidized LDL in Chronic Kidney Disease Patients on Hemodialysis and Peritoneal Dialysis , 2012, Renal failure.

[46]  J. Carrero,et al.  Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  R. Birner-Gruenberger,et al.  Uremia alters HDL composition and function. , 2011, Journal of the American Society of Nephrology : JASN.

[48]  A. Hoofnagle,et al.  Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. , 2011, Atherosclerosis.

[49]  J. Kaski,et al.  Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. , 2011, Atherosclerosis.

[50]  B. Dahlbäck,et al.  Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M , 2011, Proceedings of the National Academy of Sciences.

[51]  R. Proia,et al.  The sphingosine 1-phosphate receptor S1P2 maintains germinal center B cell homeostasis and promotes niche confinement , 2011, Nature Immunology.

[52]  B. Levkau,et al.  Sphingosine-1-Phosphate Receptor 3 Promotes Recruitment of Monocyte/Macrophages in Inflammation and Atherosclerosis , 2011, Circulation research.

[53]  Jonathan D. Smith,et al.  Sphingosine-1-Phosphate Receptor-2 Function in Myeloid Cells Regulates Vascular Inflammation and Atherosclerosis , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[54]  W. Hörl,et al.  The versatility of HDL: a crucial anti‐inflammatory regulator , 2010, European journal of clinical investigation.

[55]  Sudhir V. Shah,et al.  Chronic uremia stimulates LDL carbamylation and atherosclerosis. , 2010, Journal of the American Society of Nephrology : JASN.

[56]  Z. Massy,et al.  Atherosclerosis in CKD: differences from the general population , 2010, Nature Reviews Nephrology.

[57]  S. Tsimikas,et al.  Lipoprotein(a) accelerates atherosclerosis in uremic mice[S] , 2010, Journal of Lipid Research.

[58]  L. Nielsen,et al.  The pro-inflammatory effect of uraemia overrules the anti-atherogenic potential of immunization with oxidized LDL in apoE-/- mice. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[59]  H. Aggarwal,et al.  Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease , 2010, Renal failure.

[60]  A. Roebroek,et al.  Opposing Effects of Apolipoprotein M on Catabolism of Apolipoprotein B–Containing Lipoproteins and Atherosclerosis , 2010, Circulation research.

[61]  S. Coughlin,et al.  Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. , 2009, The Journal of clinical investigation.

[62]  M. Savolainen,et al.  Low-density lipoprotein clearance in patients with chronic renal failure. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[63]  A. Kontush,et al.  Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[64]  Anna Niemirska,et al.  Intima–media thickness measurements in children with cardiovascular risk factors , 2009, Pediatric Nephrology.

[65]  J. Spaan,et al.  Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice , 2009, Pflügers Archiv - European Journal of Physiology.

[66]  H. Moradi,et al.  Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. , 2009, Translational research : the journal of laboratory and clinical medicine.

[67]  Soo-Ho Choi,et al.  Macrophages Generate Reactive Oxygen Species in Response to Minimally Oxidized Low-Density Lipoprotein: Toll-Like Receptor 4– and Spleen Tyrosine Kinase–Dependent Activation of NADPH Oxidase 2 , 2009, Circulation research.

[68]  L. Denner,et al.  A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. , 2008, Atherosclerosis.

[69]  T. Hla,et al.  Induction of Antiproliferative Connective Tissue Growth Factor Expression in Wilms' Tumor Cells by Sphingosine-1-Phosphate Receptor 2 , 2008, Molecular Cancer Research.

[70]  G. Owens,et al.  Sphingosine-1-Phosphate Receptor Subtypes Differentially Regulate Smooth Muscle Cell Phenotype , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[71]  M. Litwin,et al.  Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[72]  Peter Stenvinkel,et al.  Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[73]  B. Porse,et al.  Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice* , 2008, Journal of Biological Chemistry.

[74]  Takuya Shimizu,et al.  Sphingosine 1-Phosphate Receptor 2 Negatively Regulates Neointimal Formation in Mouse Arteries , 2007, Circulation research.

[75]  A. Papagianni,et al.  Carotid Atherosclerosis and Endothelial Cell Adhesion Molecules as Predictors of Long-Term Outcome in Chronic Hemodialysis Patients , 2007, American Journal of Nephrology.

[76]  F. Kronenberg,et al.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Kinetic Studies of Atherogenic Lipoproteins in Hemodialysis Patients: Do They Tell Us More about Their Pathology? , 2007, Seminars in dialysis.

[77]  J. Chun,et al.  The sphingosine 1‐phosphate receptor S1P2 triggers hepatic wound healing , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[78]  T. Hla,et al.  Induction of Vascular Permeability by the Sphingosine-1-Phosphate Receptor–2 (S1P2R) and its Downstream Effectors ROCK and PTEN , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[79]  J. Witztum,et al.  Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[80]  F. Kronenberg,et al.  Lipoprotein metabolism and lipid management in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[81]  B. Levkau,et al.  The Sphingosine-1-Phosphate Analogue FTY720 Reduces Atherosclerosis in Apolipoprotein E–Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[82]  G. Assmann,et al.  FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice , 2007, Circulation.

[83]  E. Falk,et al.  Smooth Muscle Cells in Atherosclerosis Originate From the Local Vessel Wall and Not Circulating Progenitor Cells in ApoE Knockout Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[84]  B. Dahlbäck,et al.  Isolation and characterization of human apolipoprotein M-containing lipoproteins Published, JLR Papers in Press, May 8, 2006. , 2006, Journal of Lipid Research.

[85]  P. Stenvinkel,et al.  Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[86]  J. Pfeilschifter,et al.  The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells , 2006, British journal of pharmacology.

[87]  L. Nielsen,et al.  Uremia-Specific Effects in the Arterial Media During Development of Uremic Atherosclerosis in Apolipoprotein E–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[88]  F. Kronenberg,et al.  Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[89]  Z. Massy,et al.  Chronic kidney disease as cause of cardiovascular morbidity and mortality. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[90]  G. Tsujimoto,et al.  Transcriptional regulation of connective tissue growth factor by sphingosine 1‐phosphate in rat cultured mesangial cells , 2005, FEBS letters.

[91]  M. N. Poy,et al.  Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis , 2005, Nature Medicine.

[92]  J. Pfeilschifter,et al.  Sphingosine 1-Phosphate Cross-activates the Smad Signaling Cascade and Mimics Transforming Growth Factor-β-induced Cell Responses* , 2004, Journal of Biological Chemistry.

[93]  R. Proia,et al.  The Sphingosine-1-phosphate Receptors S1P1, S1P2, and S1P3 Function Coordinately during Embryonic Angiogenesis* , 2004, Journal of Biological Chemistry.

[94]  J. Chun,et al.  Lysophospholipid receptors: signaling and biology. , 2004, Annual review of biochemistry.

[95]  L. Nielsen,et al.  Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. , 2004, Journal of the American Society of Nephrology : JASN.

[96]  Peter Stenvinkel,et al.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.

[97]  Andrew C. Li,et al.  The macrophage foam cell as a target for therapeutic intervention , 2002, Nature Medicine.

[98]  D. Mazurais,et al.  Cell Type-specific Localization of Human Cardiac S1P Receptors , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[99]  T. Hla,et al.  Role of the Sphingosine 1-Phosphate Receptor EDG-1 in Vascular Smooth Muscle Cell Proliferation and Migration , 2001, Circulation research.

[100]  A. Verin,et al.  Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.

[101]  J. Dwight,et al.  Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[102]  M. Salvadori,et al.  Autoantibodies against Oxidized LDL in Chronic Renal Failure: Role of Renal Function, Diet, and Lipids , 2001, Nephron.

[103]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[104]  T Watanabe,et al.  Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. , 2000, The Biochemical journal.

[105]  M. Landray,et al.  Abnormalities of endothelial function in patients with predialysis renal failure , 2000, Heart.

[106]  J. Solski,et al.  Concentration of Lp(a) and other Apolipoproteins in Predialysis, Hemodialysis, Chronic Ambulatory Peritoneal Dialysis and Post-Transplant Patients , 2000, Clinical chemistry and laboratory medicine.

[107]  G. Bondjers,et al.  Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. , 1998, Atherosclerosis.

[108]  M. Reale,et al.  Serum Levels of Soluble Adhesion Molecules in Chronic Renal Failure and Dialysis Patients , 1998, Nephron.

[109]  S. Bhakdi,et al.  On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety , 1995, The Journal of experimental medicine.

[110]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[111]  B. Nordestgaard,et al.  Atherosclerosis and arterial influx of lipoproteins. , 1994, Current opinion in lipidology.

[112]  Hong Wang,et al.  Chronic kidney disease alters vascular smooth muscle cell phenotype. , 2015, Frontiers in bioscience.

[113]  J. Tomassini,et al.  Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. , 2013, Journal of atherosclerosis and thrombosis.

[114]  N. Vaziri,et al.  UC Irvine UC Irvine Previously Published Works Title Plasma PCSK 9 in nephrotic syndrome and in peritoneal dialysis : A cross-sectional study , 2013 .

[115]  玉眞 健一.  Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells , 2001 .

[116]  T. Kanda,et al.  Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. , 2001, The Biochemical journal.

[117]  F. Kronenberg,et al.  Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[118]  T. Kanda,et al.  Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells , 2000 .

[119]  C. Duan,et al.  Vascular Smooth Muscle Cell Proliferation and Migration Induced − Phosphatidylinositol 3-Kinase Is Required for Insulin-Like Growth Factor-I , 1999 .